The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since ...
Caldera Therapeutics, Inc. (Caldera), a clinical stage biotechnology company developing the first-in-class bispecific ...
The biotech is advancing a bispecific medicine aimed at two popular targets and being billed as a potential therapeutic advance for inflammatory bowel disease.
Discover how Caldera International is transforming pet care with innovative heated and therapeutic solutions for improved comfort and health. CANBY, OR, UNITED STATES, January 6, 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback